Literature DB >> 28470430

Is mortality due to primary malignant brain and other central nervous system tumors decreasing?

Haley Gittleman1,2, Courtney Kromer3,4, Quinn T Ostrom1,2, Rachel Blanda5, Jeffrey Russell3, Carol Kruchko2, Jill S Barnholtz-Sloan6,7.   

Abstract

Primary malignant brain and other central nervous system tumors (BT) are a rare cancer that causes morbidity and mortality disproportionate to their incidence. This study presents the most up-to-date mortality data for malignant BT in the United States (US) by histology groupings, age, race, and sex. Mortality rates for malignant BT were generated using the Center for Disease Control's National Vital Statistics Systems (NVSS, ~100% of US) data from 1975 to 2012. Histology-specific incidence-based mortality rates were calculated using the National Cancer Institute's Surveillance, Epidemiology, and End-Results 9 (SEER9, ~9.4% of US) data from 1975 to 2012. Joinpoint modeling was used to estimate trends. Mortality was similar in both the NVSS and SEER9 datasets. Overall, mortality from 1975 to 2012 was higher among men, higher in older individuals, and higher in Whites compared to other races. Persons age 65+ years had significant increases in mortality for all malignant tumors overall and for glioma histologies, while persons age <20 years had no significant changes in mortality. This study reports up-to-date mortality rates by histology groupings, age, race, and sex for malignant BT. There have been no significant changes in overall mortality due to these tumors from 1975 to 2012. There have been significant increases in mortality in the elderly (age 65+ years), especially those age 75-84 years, mirroring the effect of overall population aging. Examining age-, race-, sex-, and histology-specific morality at the population level can provide important information for clinicians, researchers, and public health planning.

Entities:  

Keywords:  Aging; Brain tumors; Glioma; Incidence-based mortality; Mortality; Time trends

Mesh:

Year:  2017        PMID: 28470430     DOI: 10.1007/s11060-017-2449-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

1.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordonna Fulop; Max Liu; Rachel Blanda; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-10-27       Impact factor: 12.300

2.  Age alone is not a predictor for survival in glioblastoma.

Authors:  Lucy Gately; Anna Collins; Michael Murphy; Anthony Dowling
Journal:  J Neurooncol       Date:  2016-07-12       Impact factor: 4.130

3.  Childhood and adolescent cancer statistics, 2014.

Authors:  Elizabeth Ward; Carol DeSantis; Anthony Robbins; Betsy Kohler; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-31       Impact factor: 508.702

4.  Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Peter M de Blank; Carol Kruchko; Claire M Petersen; Peter Liao; Jonathan L Finlay; Duncan S Stearns; Johannes E Wolff; Yingli Wolinsky; John J Letterio; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-01       Impact factor: 12.300

Review 5.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

Review 6.  The new WHO classification of brain tumours.

Authors:  P Kleihues; P C Burger; B W Scheithauer
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

7.  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.

Authors:  Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward
Journal:  Cancer       Date:  2013-12-16       Impact factor: 6.860

8.  Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.

Authors:  Ranjith Babu; Jordan M Komisarow; Vijay J Agarwal; Shervin Rahimpour; Akshita Iyer; Dylan Britt; Isaac O Karikari; Peter M Grossi; Steven Thomas; Allan H Friedman; Cory Adamson
Journal:  J Neurosurg       Date:  2015-10-09       Impact factor: 5.115

9.  Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.

Authors:  Chad G Rusthoven; Matthew Koshy; David J Sher; Douglas E Ney; Laurie E Gaspar; Bernard L Jones; Sana D Karam; Arya Amini; D Ryan Ormond; A Samy Youssef; Brian D Kavanagh
Journal:  JAMA Neurol       Date:  2016-07-01       Impact factor: 18.302

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  4 in total

1.  Machine learning: a useful radiological adjunct in determination of a newly diagnosed glioma's grade and IDH status.

Authors:  Céline De Looze; Alan Beausang; Jane Cryan; Teresa Loftus; Patrick G Buckley; Michael Farrell; Seamus Looby; Richard Reilly; Francesca Brett; Hugh Kearney
Journal:  J Neurooncol       Date:  2018-05-16       Impact factor: 4.130

2.  The association between incidence and mortality of brain cancer and human development index (HDI): an ecological study.

Authors:  Zaher Khazaei; Elham Goodarzi; Vahidreza Borhaninejad; Farhad Iranmanesh; Hosein Mirshekarpour; Batool Mirzaei; Hasan Naemi; Sayeed Maryam Bechashk; Isan Darvishi; Roghayeh Ershad Sarabi; Ahmad Naghibzadeh-Tahami
Journal:  BMC Public Health       Date:  2020-11-12       Impact factor: 3.295

3.  A Single-Center Experience of Dopamine Antagonist ONC201 for Recurrent Histone H3 Lysine 27-to-Methionine (H3K27M)-Mutant Glioblastoma in Adults.

Authors:  Chukwuyem Ekhator; Ramin Rak; Ramya Tadipatri; Ekokobe Fonkem; Jai Grewal
Journal:  Cureus       Date:  2022-08-19

Review 4.  Long non-coding RNAs mediate cerebral vascular pathologies after CNS injuries.

Authors:  Mengqi Zhang; Milton H Hamblin; Ke-Jie Yin
Journal:  Neurochem Int       Date:  2021-06-18       Impact factor: 4.297

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.